Synthesis, Characterization, and Anti-Cancer Activity of Some New N′-(2-Oxoindolin-3-ylidene)-2-propylpentane hydrazide-hydrazones Derivatives

• Published in: Molecules (Basel, Switzerland) Vol. 20; no. 8; pp. 14638 - 14655
• Main Authors: El-Faham, Ayman, Farooq, Muhammad, Khattab, Sherine, Abutaha, Nael, Wadaan, Mohammad, Ghabbour, Hazem, Fun, Hoong-Kun
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.08.2015; MDPI
• Subjects: Acids; Analgesics; anti-cancer activity; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Cancer; Cell Proliferation - drug effects; Chemistry; Crystallography; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil - pharmacology; HEK293 Cells; Hep G2 Cells; Humans; hydrazide-hydrazone; Hydrazones - chemical synthesis; Hydrazones - chemistry; Hydrazones - pharmacology; isatin; Isatin - analogs & derivatives; Isatin - chemical synthesis; Isatin - chemistry; Isatin - pharmacology; Jurkat Cells; Leukemia; Pharmaceutical sciences; valproic acid; Valproic Acid - analogs & derivatives; Valproic Acid - chemical synthesis; Valproic Acid - pharmacology; Saudi Arabia; Riyadh Saudi Arabia; anti-cancer activity; hydrazide-hydrazone; valproic acid; isatin
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules200814638

Eight novel N′-(2-oxoindolin-3-ylidene)-2-propylpentane hydrazide-hydrazone derivatives 4a–h were synthesized and fully characterized by IR, NMR (1H-NMR and 13C-NMR), elemental analysis, and X-ray crystallography. The cyto-toxicity and in vitro anti-cancer evaluation of the prepared compounds have been assessed against two different human tumour cell lines including human liver (HepG2) and leukaemia (Jurkat), as well as in normal cell lines derived from human embryonic kidney (HEK293) using MTT assay. The compounds 3e, 3f, 4a, 4c, and 4e revealed promising anti-cancer activities in tested human tumour cells lines (IC50 values between 3 and 7 μM) as compared to the known anti-cancer drug 5-Fluorouracil (IC50 32–50 μM). Among the tested compounds, 4a showed specificity against leukaemia (Jurkat) cells, with an IC50 value of 3.14 μM, but this compound was inactive in liver cancer and normal cell lines.